In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir | Zendy

Jennifer L. McKimmBreschkin | Zendy; Christina L. Rootes | Zendy; Peter G. Mohr | Zendy; Susan Barrett | Zendy; Victor A. Streltsov | Zendy

Open Access

In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir

Author(s) -

Jennifer L. McKimmBreschkin,

Christina L. Rootes,

Peter G. Mohr,

Susan Barrett,

Victor A. Streltsov

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks150

Subject(s) - zanamivir , oseltamivir , neuraminidase , virology , neuraminidase inhibitor , virus , influenza a virus , biology , resistance mutation , mutation , microbiology and biotechnology , medicine , gene , genetics , reverse transcriptase , polymerase chain reaction , covid-19 , disease , pathology , infectious disease (medical specialty)

Pandemic H1N1/09 viruses with the neuraminidase H274Y mutation have emerged in untreated patients or following oseltamivir therapy or prophylaxis. There have been no reports yet of zanamivir-resistant H1N1/09 viruses in previously healthy patients. We wanted to determine whether we could select for neuraminidase mutations conferring high-level resistance to zanamivir by in vitro passage of the virus. We also wanted to investigate if passaging in a combination of zanamivir and oseltamivir could prevent the emergence of the H274Y mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research